RATIONALE: A significant proportion of smokers have lung function impairment characterized by a reduced FEV(1) with a preserved FEV(1)/FVC ratio. These smokers are a poorly characterized group due to their systematic exclusion from chronic obstructive pulmonary disease (COPD) studies. OBJECTIVES: To characterize the clinical, functional, and radiographic features of Global Initiative for Chronic Obstructive Lung Disease (GOLD)-Unclassified (FEV(1)/FVC ≥ 0.7 and FEV(1) < 80% predicted) and lower limits of normal (LLN)-unclassified (FEV(1)/FVC ≥ LLN and FEV(1) < LLN) subjects compared to smokers with normal lung function and subjects with COPD. METHODS: Data from the first 2,500 subjects enrolled in the COPDGene study were analyzed. All subjects had 10 or more pack-years of smoking and were between the ages of 45 and 80 years. Multivariate regression models were constructed to determine the clinical and radiological variables associated with GOLD-Unclassified (GOLD-U) and LLN-Unclassified status. Separate multivariate regressions were performed in the subgroups of subjects with complete radiologic measurement variables available. MEASUREMENTS AND MAIN RESULTS: GOLD-U smokers account for 9% of smokers in COPDGene and have increased body mass index (BMI), a disproportionately reduced total lung capacity, and a higher proportion of nonwhite subjects and subjects with diabetes. GOLD-U subjects exhibit increased airway wall thickness compared to smoking control subjects and decreased gas trapping and bronchodilator responsiveness compared to subjects with COPD. When LLN criteria were used to define the "unclassified" group, African American subjects were no longer overrepresented. Both GOLD-U and LLN-Unclassified subjects demonstrated a wide range of lung function impairment, BMI, and percentage of total lung emphysema. CONCLUSIONS: Subjects with reduced FEV(1) and a preserved FEV(1)/FVC ratio are a heterogeneous group with significant symptoms and functional limitation who likely have a variety of underlying etiologies beyond increased BMI. Clinical trial registered with www.clinicaltrials.gov (NCT000608764).
RATIONALE: A significant proportion of smokers have lung function impairment characterized by a reduced FEV(1) with a preserved FEV(1)/FVC ratio. These smokers are a poorly characterized group due to their systematic exclusion from chronic obstructive pulmonary disease (COPD) studies. OBJECTIVES: To characterize the clinical, functional, and radiographic features of Global Initiative for Chronic Obstructive Lung Disease (GOLD)-Unclassified (FEV(1)/FVC ≥ 0.7 and FEV(1) < 80% predicted) and lower limits of normal (LLN)-unclassified (FEV(1)/FVC ≥ LLN and FEV(1) < LLN) subjects compared to smokers with normal lung function and subjects with COPD. METHODS: Data from the first 2,500 subjects enrolled in the COPDGene study were analyzed. All subjects had 10 or more pack-years of smoking and were between the ages of 45 and 80 years. Multivariate regression models were constructed to determine the clinical and radiological variables associated with GOLD-Unclassified (GOLD-U) and LLN-Unclassified status. Separate multivariate regressions were performed in the subgroups of subjects with complete radiologic measurement variables available. MEASUREMENTS AND MAIN RESULTS: GOLD-U smokers account for 9% of smokers in COPDGene and have increased body mass index (BMI), a disproportionately reduced total lung capacity, and a higher proportion of nonwhite subjects and subjects with diabetes. GOLD-U subjects exhibit increased airway wall thickness compared to smoking control subjects and decreased gas trapping and bronchodilator responsiveness compared to subjects with COPD. When LLN criteria were used to define the "unclassified" group, African American subjects were no longer overrepresented. Both GOLD-U and LLN-Unclassified subjects demonstrated a wide range of lung function impairment, BMI, and percentage of total lung emphysema. CONCLUSIONS: Subjects with reduced FEV(1) and a preserved FEV(1)/FVC ratio are a heterogeneous group with significant symptoms and functional limitation who likely have a variety of underlying etiologies beyond increased BMI. Clinical trial registered with www.clinicaltrials.gov (NCT000608764).
Authors: Grant Mair; John Maclay; Joy J Miller; David McAllister; Martin Connell; John T Murchison; William MacNee Journal: Respir Med Date: 2010-06-11 Impact factor: 3.415
Authors: Matthew S Brown; Hyun J Kim; Fereidoun Abtin; Irene Da Costa; Richard Pais; Shama Ahmad; Erin Angel; Chiayi Ni; Eric C Kleerup; David W Gjertson; Michael F McNitt-Gray; Jonathan G Goldin Journal: Acad Radiol Date: 2009-12-08 Impact factor: 3.173
Authors: Ravi S Aysola; Eric A Hoffman; David Gierada; Sally Wenzel; Janice Cook-Granroth; Jaime Tarsi; Jie Zheng; Kenneth B Schechtman; Thiruvamoor P Ramkumar; Rebecca Cochran; E Xueping; Chandrika Christie; John Newell; Sean Fain; Talissa A Altes; Mario Castro Journal: Chest Date: 2008-07-18 Impact factor: 9.410
Authors: George R Washko; Gary M Hunninghake; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; David A Lynch; John M Brehm; Katherine P Andriole; Alejandro A Diaz; Ramin Khorasani; Katherine D'Aco; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas Journal: N Engl J Med Date: 2011-03-10 Impact factor: 91.245
Authors: Mario Silva; Stefan F Nemec; Valerie Dufresne; Mariaelena Occhipinti; Benedikt H Heidinger; Ryan Chamberlain; Alexander A Bankier Journal: Eur Radiol Date: 2015-12-05 Impact factor: 5.315
Authors: Emily S Wan; John E Hokanson; James R Murphy; Elizabeth A Regan; Barry J Make; David A Lynch; James D Crapo; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko Journal: Am J Respir Crit Care Med Date: 2013-07-15 Impact factor: 21.405
Authors: Christopher A German; Janet S Sinsheimer; Yann C Klimentidis; Hua Zhou; Jin J Zhou Journal: Genet Epidemiol Date: 2019-12-26 Impact factor: 2.135
Authors: William W Stringer; Janos Porszasz; Surya P Bhatt; Meredith C McCormack; Barry J Make; Richard Casaburi Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: G R Washko; A A Diaz; V Kim; R G Barr; M T Dransfield; J Schroeder; J J Reilly; J W Ramsdell; A McKenzie; E J R Van Beek; D A Lynch; J P Butler; M K Han Journal: J Appl Physiol (1985) Date: 2014-01-16
Authors: C Matthew Kinsey; Raul San José Estépar; Jos van der Velden; Bernard F Cole; David C Christiani; George R Washko Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-19 Impact factor: 4.254
Authors: George R Washko; Gregory L Kinney; James C Ross; Raúl San José Estépar; MeiLan K Han; Mark T Dransfield; Victor Kim; Hiroto Hatabu; Carolyn E Come; Russell P Bowler; Edwin K Silverman; James Crapo; David A Lynch; John Hokanson; Alejandro A Diaz Journal: Acad Radiol Date: 2016-12-08 Impact factor: 3.173